Recently, urea-type compounds, 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA), trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxyl]-benzoic acid (t-AUCB), and 1-trifluoromethoxy phenyl-3-(1-acetylpiperdin-4-yl)urea (TPAU), were developed as potential inhibitors to block the catalytic reaction of sEH for the treatment of cardiovascular disease [6,11]. The gene discussed is EPHX2; the disease is cardiovascular disorder.